Ignite Creation Date:
2024-05-06 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06178770
Status:
COMPLETED
Last Update Posted:
2023-12-21
First Post:
2023-12-12
Brief Title:
Injection Intervals in Real-world Neovascular Age-related Macular Degeneration nAMD Patients Switching to Brolucizumab With at Least 12 Months of Follow-up
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Injection Intervals in Real-world Neovascular Age-related Macular Degeneration nAMD Patients Switching to Brolucizumab With at Least 12 Months of Follow-up
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This retrospective study included nAMD patients whose eyes were grouped into the following cohorts with the overall cohort receiving 1 brolucizumab injection the 12-month and 18-month brolucizumab BRO cohorts which consisted of nAMD patient eyes who switched from a previous anti-vascular endothelial growth factor VEGF and had 3 brolucizumab injections with no other anti-VEGF in the first 12 months 360 days and 18 months 540 days of follow-up respectively and the 12-month and 18-month alternating ALT cohorts which consisted of nAMD patient eyes who switched from a previous anti-VEGF to brolucizumab and had 2 brolucizumab injections and 1 injection of another anti-VEGF in the first 12 months and 18 months of follow-up respectively
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None